Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report

1. Date of report or resolution by the board of directors: 2026/05/08 2. Date of approval by the audit committee: 2026/04/28 3. Reporting period of financial report or self-audited financial information Start and end dates (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01~2026/03/31 4. Cumulative operating revenue from January 1st to the end of this period (in thousands): 1,391 5. Cumulative operating gross profit (gross loss) from January 1st to the end of this period (in thousands): 1,042 6. Cumulative operating profit (loss) from January 1st to the end of this period (in thousands): (50,802) 7. Cumulative pre-tax net profit (net loss) from January 1st to the end of this period (in thousands): (46,308) 8. Cumulative net profit (net loss) for this period from January 1st to the end of this period (in thousands): (46,308) 9. Cumulative net profit (loss) attributable to owners of parent company from January 1st to the end of this period (in thousands): (46,308) 10. Cumulative basic earnings (loss) per share from January 1st to the end of this period (in dollars): (0.53) 11. Total assets at the end of the period (in thousands): 883,757 12. Total liabilities at the end of the period (in thousands): 34,684 13. Equity attributable to owners of parent company at the end of the period (in thousands): 849,073 14. Other matters that need to be specified: None.